Moreover, the cancer-inhibiting attributes of naringin are linked to the modulation of various signaling pathways, including nuclear factor E2 related factor 2 (Nrf2), nuclear factor kappa-B (NF-κB), Phosphatidylinositol-3-kinase/Automatischer Kassentresor/Mammalian Target of Rapamycin (PI3K/Akt/mTOR), c-Jun N-terminal kinase (JNK), extracellular regulated protein kinases (ERK) and p38 Mitogen-activated protein kinase (p38 MAPK) 10. The gene discussed is MTOR; the disease is cancer.